What is ABBV stock price today?

ABBV (Abbvie Inc) stock is trading at $232.08 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ABBV stock going up or down today?

ABBV stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ABBV stock now?

The decision to buy ABBV depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ABBV a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ABBV based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ABBV stock overvalued or undervalued?

ABBV currently trades at a P/E ratio of 97.92, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if ABBV is fairly priced.

What is ABBV's P/E ratio?

ABBV has a price-to-earnings (P/E) ratio of 97.92, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ABBV's market cap?

ABBV (Abbvie Inc) has a market capitalization of $410.36 billion, making it a large-cap stock.

What is ABBV's price to book ratio?

ABBV trades at a price-to-book (P/B) ratio of 50.46, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ABBV pay dividends?

Yes, ABBV pays dividends with a current yield of 0.03%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is ABBV's dividend yield?

ABBV's dividend yield is 0.03%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is ABBV stock a good long-term investment?

ABBV's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ABBV's revenue growth rate?

ABBV has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ABBV is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in ABBV?

Key risks for ABBV include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ABBV compare to its competitors?

Compare ABBV to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ABBV's performance and positioning.

What is ABBV's stock price target for 2026?

Our AI model provides price targets for ABBV based on fundamental analysis: Bull case $301.70 (+30%), Base case $266.89 (+15%), Bear case $208.87 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ABBV?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ABBV. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ABBV's next earnings report?

ABBV reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ABBV - Abbvie Inc

NYSE * Health Care * Pharmaceuticals

$232.08

+$7.39 (+3.29%)

About Abbvie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV Key Statistics

Market Cap

$410.36B

P/E Ratio

97.92

P/B Ratio

50.46

EPS

$2.37

Dividend Yield

0.03%

Revenue Growth

+0.1%

Profit Margin

0.1%

Employees

57,000

How ABBV Compares to Peers

ABBV trades at a premium valuation vs peers (highest P/E)

ABBV is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
ABBV(This stock)	$410.36B	97.9	0%	0.1%	-
AMZNAmazon Com	$2.25T	29.3	0%	0.1%	vs AMZN

Abbvie Inc Company Information

Headquarters: Illinois; U.S.A
Website: www.abbvie.com
Sector: Health Care
Industry: Pharmaceuticals

ABBV - Abbvie Inc

About Abbvie Inc

ABBV Key Statistics

How ABBV Compares to Peers

Abbvie Inc Company Information

ABBV Lician Score

ABBV Financial Snowflake

Upcoming Events for ABBV